Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance-Reference-Cited by-同舟云学术

Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance

Published:2021-06-17 Issue:7 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Darlow Christopher A.¹^ORCID,Docobo-Perez Fernando²,Farrington Nicola¹,Johnson Adam¹,McEntee Laura¹,Unsworth Jennifer¹,Jimenez-Valverde Ana¹,Gastine Silke³^ORCID,Kolamunnage-Dona Ruwanthi⁴,de Costa Renata M. A.⁵,Ellis Sally⁵,Franceschi François⁵,Standing Joseph F.³,Sharland Mike⁶,Neely Michael⁷,Piddock Laura⁵⁸,Das Shampa¹^ORCID,Hope William¹^ORCID

Affiliation:

1. Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom

2. Departamento de Microbiología, Universidad de Sevilla, Seville, Spain

3. Great Ormond Street Institute of Child Health, University College London, London, United Kingdom

4. Department of Health Data Science, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom

5. Global Antibiotic Research and Development Partnership, Geneva, Switzerland

6. Paediatric Infectious Diseases Research Group, St. George’s University of London, London, United Kingdom

7. Children’s Hospital Los Angeles and the Keck School of Medicine, University of Southern California, Los Angeles, California, USA

8. Antimicrobials Research Group, School of Immunity and Infection, Institute for Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom

Abstract

Antimicrobial resistance (particularly through extended-spectrum β-lactamase and aminoglycoside-modifying enzyme production) in neonatal sepsis is a global problem, particularly in low- and middle-income countries, with significant mortality rates. High rates of resistance are reported for the current WHO-recommended first-line antibiotic regimen for neonatal sepsis, i.e., ampicillin and gentamicin.

Funder

Global Antibiotic Research and Development Partnership

UKRI | Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00293-21

Reference55 articles.

1. Neonatal sepsis

2. Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013

3. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis

4. Fuchs A, Bielicki J, Mathur S, Sharland M, Van Den Anker JN. 2016. Antibiotic use for sepsis in neonates and children: 2016 evidence update. World Health Organization, Geneva, Switzerland.

5. World Health Organization. 2013. Pocket book of hospital care for children, 2nd ed. World Health Organization, Geneva, Switzerland.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment;CPT: Pharmacometrics & Systems Pharmacology;2024-01-03

2. Identification of potential novel combination antibiotic regimens based on drug-susceptibility and genetic diversity of Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries;2023-10-24

3. Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia;International Journal of Antimicrobial Agents;2022-10

4. Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings;Journal of Antimicrobial Chemotherapy;2022-09-30

5. Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance;Antimicrobial Agents and Chemotherapy;2022-04-19